Nephrotoxicity of piperacillin/tazobactam combined with vancomycin: should it be a concern?

International Journal of Antimicrobial Agents

Volumn 52, Issue 2, 2018, Pages 180-184

  Balcı, Cafer ^a   Uzun, Ömrüm ^a   Arıcı, Mustafa ^a   Hayran, Sibel Aşçıoğlu ^a,b   Yüce, Deniz ^a   Ünal, Serhat ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

^b GLAXOSMITHKLINE   (Singapore)

Author keywords

Acute kidney injury; Meropenem; Nephrotoxicity; Piperacillin tazobactam; Vancomycin

Indexed keywords

CREATININE; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN; PENICILLANIC ACID; PIPERACILLIN; PIPERACILLIN, TAZOBACTAM DRUG COMBINATION; THIENAMYCIN DERIVATIVE;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; INCIDENCE; INJURY SEVERITY; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIVARIATE ANALYSIS; NEPHROTOXICITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; AGED; ANALOGS AND DERIVATIVES; BLOOD; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; DRUG EFFECT; GROWTH, DEVELOPMENT AND AGING; KIDNEY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGY; MIDDLE AGED; PATHOLOGY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; STAPHYLOCOCCUS INFECTION; STATISTICAL MODEL;

ACUTE KIDNEY INJURY; ADULT; AGED; CREATININE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; KIDNEY; LOGISTIC MODELS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; PENICILLANIC ACID; PIPERACILLIN; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; THIENAMYCINS; VANCOMYCIN;

EID: 85048986510     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2018.03.024     Document Type: Article

References (22)

1. Schetz, M, Dasta, J, Goldstein, S, Golper, T, Drug-induced acute kidney injury. Curr Opin Crit Care 11 (2005), 555–565.
2. Bentley, ML, Corwin, HL, Dasta, J, Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies. Crit Care Med 38 (2010), S169–S174.
3. Lipsky, BA, Berendt, AR, Cornia, PB, Pile, JC, Peters, EJ, Armstrong, DG, et al. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis 54 (2012), e132–e173.
4. Stevens, DL, Bisno, AL, Chambers, HF, Dellinger, EP, Goldstein, EJ, Gorbach, SL, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis 59 (2014), 147–159.
5. Solomkin, JS, Mazuski, JE, Bradley, JS, Rodvold, KA, Goldstein, EJ, Baron, EJ, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis 50 (2010), 133–164.
6. Elyasi, S, Khalili, H, Dashti-Khavidaki, S, Mohammadpour, A, Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review. Eur J Clin Pharmacol 68 (2012), 1243–1255.
7. Zosyn (Piperacillin-tazobactam) package insert. Wyeth Pharmaceuticals Inc. Philadephia, PA. 2012.
8. Burgess, LD, Drew, RH, Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin-tazobactam. Pharmacotherapy 34 (2014), 670–676.
9. Peyko, V, Smalley, S, Cohen, H, Prospective comparison of acute kidney injury during treatment with the combination of piperacillin-tazobactam and vancomycin versus the combination of cefepime or meropenem and vancomycin. J Pharm Pract 30 (2017), 209–213.
10. Gomes, DM, Smotherman, C, Birch, A, Dupree, L, Della Vecchia, BJ, Kraemer, DF, et al. Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or cefepime. Pharmacotherapy 34 (2014), 662–669.
11. Gilbert, DN, Moellering, RC Jr Jr, Eliopoulos, GM, (eds.) The Sanford guide to antimicrobial therapy 2012, 2012, Antimicrobial Therapy, Inc., Sperryville, VA.
12. Mehta, RL, Kellum, JA, Shah, SV, Molitoris, BA, Ronco, C, Warnock, DG, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care, 11, 2007, R31.
13. McQueen, KE, Clark, DW, Does combination therapy with vancomycin and piperacillin-tazobactam increase the risk of nephrotoxicity versus vancomycin alone in pediatric patients?. J Pediatr Pharmacol Ther 21 (2016), 332–338.
14. Giuliano, CA, Patel, CR, Kale-Pradhan, PB, Is the combination of piperacillin-tazobactam and vancomycin associated with development of acute kidney injury? A meta-analysis. Pharmacotherapy 36 (2016), 1217–1228.
15. Jeon, N, Staley, B, Klinker, KP, Hincapie Castillo, J, Winterstein, AG, Acute kidney injury risk associated with piperacillin/tazobactam compared with cefepime during vancomycin therapy in hospitalised patients: a cohort study stratified by baseline kidney function. Int J Antimicrob Agents 50 (2017), 63–67.
16. Moenster, RP, Linneman, TW, Finnegan, PM, Hand, S, Thomas, Z, McDonald, JR, Acute renal failure associated with vancomycin and β-lactams for the treatment of osteomyelitis in diabetics: piperacillin-tazobactam as compared with cefepime. Clin Microbiol Infect 20 (2014), O384–O389.
17. Min, E, Box, K, Lane, J, Sanchez, J, Coimbra, R, Doucet, J, et al. 714: acute kidney injury in patients receiving concomitant vancomycin and piperacillin/tazobactam. Crit Care Med, 39, 2011, 200.
18. Meaney, CJ, Hynicka, LM, Tsoukleris, MG, Vancomycin‐associated nephrotoxicity in adult medicine patients: incidence, outcomes, and risk factors. Pharmacotherapy 34 (2014), 653–661.
19. Baldwin, DS, Levine, BB, McCluskey, RT, Gallo, GR, Renal failure and interstitial nephritis due to penicillin and methicillin. N Engl J Med 279 (1968), 1245–1252.
20. Liu, P, Tepperman, BS, Logan, AG, Acute renal failure induced by semi-synthetic penicillins. Can Fam Physician, 27, 1981, 507.
21. Rutter, WC, Cox, JN, Martin, CA, Burgess, DR, Burgess, DS, Nephrotoxicity during vancomycin therapy in combination with piperacillin-tazobactam or cefepime. Antimicrob Agents Chemother, 61: 2017 e02089-16.
22. Al Yami, MS, Comparison of the incidence of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or with meropenem. J Infect Public Health 10 (2017), 770–773.